The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICLE 2022 | Is WT1 a promising candidate peptide for TCR-based immunotherapies?
T cell receptor (TCR)–modified T cell therapies show clinical potential for the treatment of different cancers however a key challenge is the identification of optimal target antigens. Chiara Bonini, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Institute, Milan, Italy, highlights Wilms’ tumor antigen 1 (WT1) as a candidate peptide for TCR-based cancer therapies, which is immunogenic, widely expressed by many tumors and important for blast cell survival. She describes the identification of a WT1-specific TCR with high avidity that is naturally processed by acute myeloid leukemia (AML) cells and has the ability to recognize human leukocyte antigen class II (HLA-II) peptides. T cells engineered to express this TCR are being advanced into clinical development for AML immunotherapy. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.
